三诺生物(300298) - 2022 Q3 - 季度财报

Financial Performance - Revenue for Q3 2022 reached ¥688,579,127.87, an increase of 11.38% year-over-year, while total revenue for the year-to-date was ¥1,980,530,135.94, up 13.23% compared to the same period last year[4]. - Net profit attributable to shareholders for Q3 2022 was ¥153,470,946.83, representing a significant increase of 97.16% year-over-year, with a year-to-date net profit of ¥363,402,542.22, up 84.60%[4]. - The basic earnings per share for Q3 2022 was ¥0.2754, an increase of 99.57% compared to the same period last year, while the diluted earnings per share also stood at ¥0.2754[4]. - Operating profit for Q3 2022 was ¥395,736,205.01, up 94.39% year-over-year, driven by increased revenue and investment income[9]. - Net profit for the period was CNY 363,176,064.00, compared to CNY 196,550,398.85 in the same period last year, representing an increase of 84.8%[35]. - Earnings per share (EPS) for the period was CNY 0.6499, up from CNY 0.3489 in the previous year, indicating a significant improvement in profitability[35]. Assets and Equity - The company's total assets as of September 30, 2022, were ¥4,488,728,026.27, reflecting an 8.07% increase from the end of the previous year[4]. - The company's total equity attributable to shareholders increased to ¥3,070,318,315.88, a rise of 10.22% from the end of the previous year[4]. - The company's total assets reached RMB 4,488.73 million as of September 30, 2022, compared to RMB 4,153.51 million at the beginning of the year[31]. - The total equity attributable to shareholders of the parent company rose to CNY 3,070,318,315.88, compared to CNY 2,785,671,986.48, marking an increase of 10.3%[32]. Cash Flow - The net cash flow from operating activities for the year-to-date was ¥352,578,588.84, an increase of 84.96% compared to the same period last year[4]. - The cash inflow from operating activities totaled CNY 2,156,263,232.40, an increase from CNY 1,778,397,923.26 in the previous year, representing a growth of approximately 21.3%[37]. - The net cash flow from operating activities was CNY 352,578,588.84, compared to CNY 190,619,407.31 in the same period last year, indicating a significant increase of about 84.9%[37]. - The cash inflow from investment activities totaled ¥321,410,374.30, reflecting a 108.67% increase, mainly driven by the redemption of financial products by the parent company[11]. - The cash outflow from investing activities was CNY 393,331,125.46, down from CNY 572,244,702.06, showing a reduction of approximately 31.3%[38]. - The total cash and cash equivalents at the end of the period amounted to CNY 514,124,568.01, down from CNY 634,868,492.55 in the previous year, a decrease of about 19.0%[38]. Investment Income - Investment income for Q3 2022 was ¥59,377,166.73, a substantial increase of 286.34% compared to the previous year, primarily due to compensation received from a subsidiary[9]. - The company reported investment income of CNY 59,377,166.73, a recovery from a loss of CNY 31,864,684.38 in the same period last year[34]. - The cash inflow from investment income increased by 215.31% to ¥3,216,192.28, attributed to higher returns from redeemed financial products[11]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 10,905[12]. - The largest shareholder, Li Shaobo, holds 25.29% of the shares, amounting to 142,685,648 shares, with 92,585,000 shares pledged[13]. - The company repurchased a total of 6,999,287 shares, accounting for 1.24% of the total share capital of 564,221,835 shares, with a total transaction amount of RMB 168,585,184.23[20]. Research and Development - Research and development expenses for the period were CNY 183,462,004.12, up from CNY 143,218,412.66, reflecting a year-over-year increase of 28.1%[34]. Financial Management - The company reported a significant reduction in financial expenses, down 102.39% to -¥771,948.28, mainly due to decreased interest expenses[9]. - The cash received from tax refunds was CNY 39,248,524.61, compared to CNY 21,132,926.18 in the previous year, representing an increase of approximately 85.7%[37].